GlaxoSmithKline
NEWS
There has been a flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites. Here’s a look.
It’s a busy week for GlaxoSmithKline, although much of it is related to the upcoming demerger of its Consumer Healthcare business. Here’s a look.
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
Master planning for the site is slated to begin in 2022 and will reportedly create one of the largest life sciences cluster in Europe.
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
Philip Morris will acquire Vectura to gain access to its inhaled drug formulas to bolster its Beyond Nicotine strategy.
Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.
The two antibody candidates, AL001 and AL101, are seen as potential first-in-class medications aimed at a range of neurodegenerative diseases.
JOBS
IN THE PRESS